Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention

Mishra, Abhishek MD*; Singh, Maninder MD*; Acker, Warren W. MS*,†; Kamboj, Sukriti MD; Sporn, Daniel MD*; Stapleton, Dwight MD§; Kaluski, Edo MD*,†,¶

Journal of Cardiovascular Pharmacology: August 2019 - Volume 74 - Issue 2 - p 82–90
doi: 10.1097/FJC.0000000000000697
Review Article
Buy
SDC

Aim: The objective of this article is to review the contemporary literature on the use of antithrombotic therapy in patients with atrial fibrillation (AF) and coronary artery disease after undergoing percutaneous coronary intervention (PCI). Special consideration was given to the type and duration of therapy, treatment strategies for the elderly (≥65 years of age), and strategies to reduce bleeding.

Methods: Relevant studies were searched through MEDLINE/PubMed, Web of Science, Cochrane Library, ClinicalTrials.gov, and Google Scholar. Of the 236 publications retrieved, 76 were considered relevant including 35 randomized controlled trials, 17 meta-analyses, 16 observational studies, and 8 published major guidelines.

Results: Most trials, meta-analyses, and guidelines support 1 month of triple therapy (TT) with an oral anticoagulant (OAC), dual antiplatelet agents (DAPT) with aspirin (ASA)/clopidogrel, and, afterward, dual therapy (DT) with OAC and single antiplatelet agent for an additional 11 months, or alternatively DT alone for 12 months after PCI. Individual consideration is given to the risk and impact of stent thrombosis (ST), thromboembolism, and bleeding. Several trials and meta-analyses have also suggested that shorter DAPT duration (≤6 months) may be safer than longer therapy (≥6 months) when weighing the risk of bleeding with ischemic outcomes, especially with newer generation drug-eluting stents. The selective use of proton-pump inhibitors in patients prone to gastrointestinal bleeding who are subjected to prolonged exposure with TT or DT may be beneficial. In the elderly, the risk of bleeding from TT, compared with DT, outweighs the benefit of reducing ischemic events.

Conclusions: In conclusion, tailoring therapy to the individual patient is recommended considering the ischemic and bleeding risk as well as the risk of thromboembolism. For most patients with AF, 1 month of TT and subsequently DT for additional 11 months are recommended.

*Heart and Vascular Center, Guthrie/Robert Packer Hospital, Sayre, PA;

Geisinger Commonwealth School of Medicine, Scranton, PA;

East Carolina University, Greenville NC;

§OSF Healthcare System, University of Illinois College of Medicine, Peoria, IL; and

Rutgers University, New Brunswick, NJ.

Reprints: Abhishek Mishra, MD, Department of Cardiovascular Disease, One Guthrie Square, The Guthrie Clinic/Robert Packer Hospital, Sayre, PA 18840 (e-mail: Abhishek_110@hotmail.com).

The authors report no conflicts of interest.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jcvp.org).

M. Singh and W. W. Acker share equal contribution to this article.

The authors are solely responsible for drafting and editing of the manuscript and its final contents. All authors had a role in writing the manuscript.

Received February 07, 2019

Accepted May 15, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.